Company intelligence / Profile preview

Nuritas

Ownership: Private
Employees: ~125
Development stage: Commercial

Overview

Nuritas uses its proprietary AI-driven platform to discover and clinically validate bioactive peptides from natural sources. Its ingredients have demonstrated efficacy in human clinical trials with over an 80% success rate at the clinical stage. Products such as PeptiStrong® have received FDA GRAS approval for food applications. The company conducts double-blind, third-party validated clinical trials for its products.

Therapeutic areas: Metabolic DisordersDermatologyEndocrinologyNeurology
Modalities: Bioactive peptides (cell-signaling and functional peptides)
Industry: Non-Drug Biotech

Drug pipeline

3 assets

PeptiStrong

Commercial

Indications: Muscle health, Muscle recovery, Anti-inflammation

2 more assets in the full pipeline.

Request access →

Partnerships

GivaudanNestléSumitomo Corporation

Beyond the preview

Go deeper on Nuritas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuritas.

Explore the full profile